Literature DB >> 19483723

p53 and little brother p53/47: linking IRES activities with protein functions.

R Grover1, M M Candeias, R Fåhraeus, S Das.   

Abstract

The tumor suppressor p53 represents a paradigm for gene regulation. Its rapid induction in response to DNA damage conditions has been attributed to both increased half-life of p53 protein and also increased translation of p53 mRNA. Recent advances in our understanding of the post-transcriptional regulation of p53 include the discovery of internal ribosome entry sites (IRESs) within the p53 mRNA. These IRES elements regulate the translation of the full length as well as the N-terminally truncated isoform, p53/47. The p53/47 isoform is generated by alternative initiation at an internal AUG codon present within the p53 ORF. The aim of this review is to summarize the role of translational control mechanisms in regulating p53 functions. We discuss here in detail how diverse cellular stress pathways trigger alterations in the cap-dependent and cap-independent translation of p53 mRNA and how changes in the relative expression levels of p53 isoforms result in more differentiated p53 activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483723     DOI: 10.1038/onc.2009.138

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Reversible induction of translational isoforms of p53 in glucose deprivation.

Authors:  D Khan; A Katoch; A Das; A Sharathchandra; R Lal; P Roy; S Das; S Chattopadhyay; S Das
Journal:  Cell Death Differ       Date:  2015-02-27       Impact factor: 15.828

Review 2.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

Review 3.  Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states.

Authors:  Anton A Komar; Maria Hatzoglou
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

4.  The amyloid precursor protein (APP) intracellular domain regulates translation of p44, a short isoform of p53, through an IRES-dependent mechanism.

Authors:  Mi Li; Mariana Pehar; Yan Liu; Anita Bhattacharyya; Su-Chun Zhang; Kenneth J O'Riordan; Corinna Burger; Luciano D'Adamio; Luigi Puglielli
Journal:  Neurobiol Aging       Date:  2015-06-21       Impact factor: 4.673

5.  A single synonymous mutation determines the phosphorylation and stability of the nascent protein.

Authors:  Konstantinos Karakostis; Sivakumar Vadivel Gnanasundram; Ignacio López; Aikaterini Thermou; Lixiao Wang; Karin Nylander; Vanesa Olivares-Illana; Robin Fåhraeus
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

6.  Length variants of the 5' untranslated region of p53 mRNA and their impact on the efficiency of translation initiation of p53 and its N-truncated isoform ΔNp53.

Authors:  Agnieszka Górska; Leszek Błaszczyk; Mariola Dutkiewicz; Jerzy Ciesiołka
Journal:  RNA Biol       Date:  2013-11       Impact factor: 4.652

7.  p53 isoform profiling in glioblastoma and injured brain.

Authors:  R Takahashi; C Giannini; J N Sarkaria; M Schroeder; J Rogers; D Mastroeni; H Scrable
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

Review 8.  Regulation of tumor suppressor p53 at the RNA level.

Authors:  Anna Vilborg; Margareta T Wilhelm; Klas G Wiman
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

9.  Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma.

Authors:  Xiaoli Yang; Peng Zou; Jun Yao; Dong Yun; Huimin Bao; Ruyun Du; Jing Long; Xian Chen
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

10.  p53 binds the mdmx mRNA and controls its translation.

Authors:  A-S Tournillon; I López; L Malbert-Colas; S Findakly; N Naski; V Olivares-Illana; K Karakostis; B Vojtesek; K Nylander; R Fåhraeus
Journal:  Oncogene       Date:  2016-07-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.